Generate Biomedicines, Inc. (GENB) stock
Close on Nov 13, 2026Market cap $1.55BP/E –Yield –
Generate Biomedicines statistics
37 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 4.06
- 2.22
Share statisticsIndustry
- Shares Change (QoQ)
- 0.59%
- 0.50%
- Float
- 56M
- 49M
- Shares Held by Insiders
- 56.0%
- 11.7%
- Shares Held by Institutions
- 77.9%
- 56.4%
Short sellingIndustry
- Short Interest
- 9M
- –
- Short Interest Change
- 1.73%
- -0.80%
- Short % of Float
- 16.1%
- 9.01%
- Short % of Shares Outstanding
- 7.08%
- 6.30%
- Days to Cover
- 8.87
- 5.15
Stock price statisticsIndustry
- 20-Day Moving Average
- $13.39
- –
- 50-Day Moving Average
- $14.35
- –
- Average True Range (14)
- $1.09
- –
- Price Change (1 Week)
- -7.58%
- -1.15%
- Price Change (1 Month)
- -7.58%
- -4.87%
- Price Change (3 Months)
- -23.1%
- -21.0%
- Price Change (6 Months)
- -24.6%
- -20.6%
- Average Volume (10 Days)
- 811,821
- –
- Average Volume (20 Days)
- 925,846
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 0.80
- 0.70
- Relative Strength Index (14)
- 41.4
- 43.4
- Volatility (1 Year)
- 87.7%
- 80.1%
Financial positionIndustry
- Current Ratio
- 5.01
- 3.30
- Quick Ratio
- 4.89
- 2.39
Balance sheetIndustry
- Net Cash (Debt)
- $404.20M
- $17.76M
- Net Cash Per Share
- $3.15
- $0.80
- Equity (Book Value)
- $381.16M
- $53.89M
- Book Value Per Share
- $2.97
- $1.50
- Tangible Book Value
- $381.16M
- $27.13M
- Working Capital
- $331.92M
- $79.99M
Scores and fair valueIndustry
- Altman Z-Score
- 5.25
- 0.23
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | GENB | S&P 500 | Difference | GENB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.5% | -3.0% | +1.5 pts | ||
| 3 months | -19.7% | -2.8% | −16.9 pts |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
9M GENB shares were sold short on Oct 30, 2026, up 1.7% from the previous report, or 16.10% of the shares available to trade. At recent volumes it would take 8.9 days to buy them back. Over the last 20 sessions, 70.0% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 9,084,724 | +1.7% | 1,023,797 | 8.9 |
| Oct 15, 2026 | 8,930,609 | +20.4% | 1,118,384 | 8.0 |
| Sep 30, 2026 | 7,417,094 | +3.3% | 1,289,467 | 5.8 |
| Sep 15, 2026 | 7,180,013 | -3.7% | 991,064 | 7.2 |
| Aug 31, 2026 | 7,456,033 | +2.3% | 1,993,671 | 3.7 |
| Aug 14, 2026 | 7,286,295 | +0.1% | 482,706 | 15.1 |
| Jul 31, 2026 | 7,275,413 | +4.1% | 477,224 | 15.3 |
| Jul 15, 2026 | 6,985,520 | +18.1% | 744,702 | 9.4 |
| Jun 30, 2026 | 5,916,840 | +30.1% | 1,467,640 | 4.0 |
| Jun 15, 2026 | 4,548,820 | +11.3% | 939,384 | 4.8 |
| May 29, 2026 | 4,087,393 | +18.3% | 843,880 | 4.8 |
| May 15, 2026 | 3,453,784 | +8.7% | 404,364 | 8.5 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?